Aimmune Therapeutics Inc (AIMT) was Initiated by JMP Securities to “Mkt Outperform”. JMP Securities advised their investors in a research report released on Sep 26, 2016.
In a different news, on Sep 9, 2016, Mary M. Rozenman (officer ) sold 30,000 shares at $16.80 per share price. According to the SEC, on Aug 11, 2015, Mark T Iwicki (director) purchased 20,000 shares at $16.00 per share price. On Aug 11, 2015, Mark Mcdade (director) purchased 16,660 shares at $16.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Aimmune Therapeutics Inc formerly Allergen Research Corporation is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach including the development of proprietary candidates for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products defined treatment protocols and support services. Its lead product AR101 which has completed a Phase II study is designed to treat peanut allergy. The Company’s AR101 is a mixture of naturally occurring proteins and pharmaceutical-grade ingredients. Its CODIT system aims to improve upon oral immunotherapy (OIT) by precisely controlling the amount of food protein administered and establishing very gradual treatment regimens that begin with low doses of protein.